Researchers sought to determine whether patients with T-ALL would be responsive to salvage therapy with homoharringtonine, cytarabine, and aclarubicin.

Eric Gené will join the TCR Europe grid for a full-time programme in 2025 after being named as the second driver in the ...

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The US regulator ...

Hum Gene Ther 2023;34(15-16):682-696 ... Vector-mediated delivery of human MHC-I into hepatocytes enables investigation of TCR-redirected HBV-specific T cells in mice and macaque cell cultures.

One asset, dubbed ADP-600, is designed to target indications that express PRAME—a protein coding gene—such as synovial ... a MAGE-4A TCR T-cell therapy. However, enrollment in two clinical ...